What kills a cancer cell can kill a parasite, provided the difference is selective.
For generations, African trypanosomiasis has extracted a quiet, devastating toll across sub-Saharan Africa — killing with the parasite, and sometimes with the cure itself. Now, a team of researchers has found that molecules designed to fight cancer may carry within them an unexpected answer to this ancient affliction, demonstrating that the boundaries between diseases are more porous than medicine once assumed. Two compounds from a shared library of kinase inhibitors have shown the capacity to destroy Trypanosoma brucei parasites swiftly and selectively, without harming human cells — a small but meaningful light in a field that has gone decades without a genuinely new weapon.
- Over 55 million people remain exposed to a disease whose frontline treatments can trigger fatal brain inflammation in up to one in ten patients — the cure itself a form of danger.
- No new drug for animal trypanosomiasis has emerged in decades, leaving livestock economies across sub-Saharan Africa at the mercy of parasites that have learned to resist the only tools available.
- Researchers bypassed the slow, expensive path of designing new molecules and instead screened 250 existing cancer and inflammation compounds, betting that what disrupts a tumor cell's kinase might disrupt a parasite's as well.
- Two compounds — OGHL00006 and OGHL00169 — killed parasites completely within hours to days at doses that left human cells unharmed, with molecular modeling suggesting they jam or block kinases essential to parasite survival.
- The findings remain early-stage: tested only in laboratory dishes on a single parasite strain, with unresolved questions around solubility, metabolism, and behavior in living organisms still standing between discovery and treatment.
African trypanosomiasis — sleeping sickness in humans, nagana in livestock — has shadowed sub-Saharan Africa for generations. More than 55 million people remain at risk, and the drugs available to treat them carry a grim irony: melarsoprol, an arsenic-based compound still in use, kills patients outright in five to ten percent of cases through fatal brain inflammation. Newer medicines have improved outcomes for one parasite subspecies, but leave the more aggressive strain untreated. For animal trypanosomiasis, the situation is bleaker — no genuinely new drug has arrived in decades, and resistance to the aging arsenal is now routine.
Rather than building new molecules from scratch, a research team took a more pragmatic route: they screened 250 compounds from Merck's Open Global Health Library, a collection originally developed for cancer and inflammation. The reasoning was elegant — kinases, the proteins these drugs were designed to disrupt, are conserved across species. What jams a cancer cell's growth machinery might do the same to a parasite.
Two compounds stood out. OGHL00006 killed parasites within four hours; OGHL00169 achieved complete parasite death within 24 to 36 hours, with no regrowth observed over three days. Both were selective, sparing human cells at therapeutic concentrations. Molecular modeling suggested OGHL00006 permanently binds a parasite kinase called TbCLK1, while OGHL00169 reversibly targets TbPDK1 — both proteins essential to parasite survival.
The approach reflects drug repurposing at its most efficient. Several of the screened compounds had already shown activity against malaria or schistosomiasis, meaning their safety profiles and pharmacological behavior were partially understood. Researchers were not starting blind — they were asking new questions of well-characterized tools.
The work remains preliminary. All experiments were conducted in laboratory conditions using a single parasite strain; the human-infective subspecies and animal parasites have not yet been tested. Questions of solubility, metabolism, and tissue penetration remain open. Some compounds will need chemical refinement before they can function reliably in a living organism.
Still, the findings offer something the field has lacked: a credible structural starting point. The researchers have identified chemical frameworks that can be optimized, and demonstrated that phenotypic screening — testing compounds directly on whole parasites — can reveal mechanisms that more targeted approaches might overlook. In a landscape where patients face drugs that poison them and parasites that resist those poisons, this represents a genuine, if early, opening.
African trypanosomiasis—sleeping sickness in humans, nagana in livestock—has haunted sub-Saharan Africa for generations. Over 55 million people remain at risk. The drugs that treat it are old, toxic, and increasingly ineffective. Melarsoprol, an arsenic compound used for decades, kills patients outright in 5 to 10 percent of cases, triggering fatal brain inflammation. Newer options like fexinidazole and acoziborole have improved the picture for one form of human disease, but they work only against a single parasite subspecies, leaving the more aggressive strain untouched. For animal trypanosomiasis—which devastates livestock and the rural economies that depend on them—the situation is grimmer still. No genuinely new drug has arrived in several decades. The arsenal consists of compounds so old and problematic that resistance is now routine.
Instead of designing drugs from scratch, a team of researchers took a different path. They screened 250 existing compounds from Merck's Open Global Health Library, a collection of molecules originally developed for cancer, inflammation, and other human diseases. The logic was simple: if a drug can disrupt a kinase—a protein that controls cell growth—in a cancer cell, perhaps it can do the same in a parasite. The parasites and human cells share enough molecular machinery that the overlap is real.
Three compounds emerged from the initial screen with genuine promise. Two of them—labeled OGHL00006 and OGHL00169—proved exceptional. OGHL00006 killed parasites within four hours. OGHL00169 took longer, requiring 24 to 36 hours, but the result was the same: complete parasite death at therapeutic doses, with no regrowth over three days. Both compounds were selective, meaning they poisoned the parasites without harming human cells at the concentrations needed. The third compound, OGHL00133, worked differently—it slowed parasite growth rather than killing outright, a less desirable mechanism for a drug.
The researchers used molecular modeling to understand how these compounds worked. OGHL00006, which contains a reactive chemical group called a Michael acceptor, appears to bind permanently to a parasite kinase called TbCLK1, essentially jamming the protein. OGHL00169 targets a different kinase, TbPDK1, through reversible binding. Both kinases are essential for parasite survival. The fact that these compounds were originally designed to fight cancer—where they target similar kinases in human tumor cells—explains their potency. Kinases are conserved across species. What kills a cancer cell can kill a parasite, provided the parasite's version of the kinase is sufficiently different from the human version to allow selectivity.
This is drug repurposing at its most elegant. Rather than spending a decade and hundreds of millions of dollars designing a new molecule from first principles, researchers mined an existing library of well-characterized compounds. Six of the compounds they identified had already shown activity against malaria parasites in earlier screens. Four had demonstrated efficacy against schistosomiasis. The compounds were not random; they were molecules that had already proven their safety and pharmacological properties in human trials or advanced development. The researchers simply asked a new question of old tools.
The work is preliminary. The experiments were conducted in test tubes and petri dishes, using a laboratory strain of the parasite. The two human-infective subspecies—T. b. gambiense and T. b. rhodesiense—have not yet been tested. Neither have the animal parasites. The compounds' behavior in living organisms remains unknown. Solubility, metabolism, and the ability to reach infected tissues are all open questions. One compound showed poor solubility; another cleared from the body too quickly. These are not insurmountable problems, but they are real ones that will require chemical modification to solve.
Yet the findings point toward a path forward. The researchers have identified chemical scaffolds—structural frameworks—that can be refined and optimized. They have demonstrated that kinase inhibitors developed for one disease can work against a parasite that kills millions. They have shown that phenotypic screening—testing compounds directly on whole parasites rather than isolated molecular targets—can uncover mechanisms of action that traditional target-based approaches might miss. In a field starved for new options, where patients face drugs that poison them and parasites that resist those poisons, this is a genuine opening.
Citações Notáveis
Current antitrypanosomal therapies are compromised by issues of drug resistance and toxicity, highlighting an urgent need for novel therapeutic options.— Study authors
OGHL00006 and OGHL00169 induced rapid and irreversible growth arrest of parasites within 4–24 hours of incubation.— Study findings
A Conversa do Hearth Outra perspectiva sobre a história
Why does a cancer drug work against a parasite?
Because both cancer cells and parasites need kinases to survive and grow. A kinase is a protein that controls when cells divide and when they die. Cancer cells need to divide constantly. Parasites need to divide constantly too. If you jam the kinase, you stop both. The trick is finding a kinase that's different enough between the parasite and the human that you can poison one without poisoning the other.
But cancer drugs are toxic. People take them knowing they'll feel terrible.
True, but the toxicity is usually dose-dependent. At the concentration needed to kill the parasite, these compounds didn't harm human cells in the lab. That's what selectivity means. The parasite's kinase is apparently more vulnerable than the human version, or the human cells can tolerate the drug better. We don't know yet—that's what needs testing in living animals.
Why hasn't anyone tried this before?
They have, in pieces. People have known that kinase inhibitors can work against parasites. But this is the first systematic screening of a large, well-characterized library against trypanosomiasis. Merck made the library freely available. That matters. Most pharmaceutical companies keep their compounds proprietary. Open access changes what's possible.
What happens next?
The compounds need to be tested against the actual parasites that infect humans and animals. They need to be tested in mice and other animals to see if they work in a living body, how they're metabolized, whether they reach the brain—which is crucial for sleeping sickness. Some will probably fail. But if even one makes it through, it could be a new option for patients who have none.
How long will that take?
Years. Maybe five to ten before you'd see a clinical trial. But that's fast compared to designing a drug from scratch, which takes fifteen to twenty years. Repurposing accelerates everything because you already know the compound is safe enough for humans.
And if it works?
Then 55 million people at risk have a new choice. And livestock in rural Africa have a treatment that actually works. That changes the economics of entire regions.